DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 01 · Volume 18 · January 1985 DOI: 10.1055/s-002-10193

EDITORIAL

  • 1
    Netter, P.; Beckmann, H.:

    Congress of the AGNP, Nuremberg 1983

    • GERONTOPSYCHIATRY

  • 2
    Heimann, H.:

    Clinical Aspects of Dementia Syndrome

  • 6
    Häfner, H.:

    Mental Disorder in Old Age - Medical and Social Risk Factors

  • 12
    Koeppen, D.; Netter, P.; Fischer, C.:

    Individual Differences in the Effects of Clobazam on Memory Functions - Clobazam and Memory

  • 15
    Albus, M.; Ackenheil, M.; Engel, R. R.; Müller-Spahn, F.; Stahl, S.:

    Influence of Beta-Blockers and/or Minor Tranquilizers on Autonomic Stress Reactions

  • 17
    Depoortere, H.:

    A Comparative EEG Study of Some Benzodiazepine (BZD) and Non-BZD Sedative or Hypnotic Drugs

  • 20
    Hoff, P.; Dieterle, D.; Eben, E.:

    The Effect of CGP 361 A, a New Beta-blocking Compound, on In-patients with Anxiety

  • 22
    Ruhland, M.:

    Metaclazepam - a New Anxiolytic Benzodiazepine with Selective Tolerance and Crosstolerance to Other Benzodiazepines

  • 24
    Richter, W.; Giertz, H.:

    The Effect of Supidimide and Lormetazepam on Sleep - A Controlled Clinical Study in Outpatients

  • 27
    Dirschedl, P.; Hasford, J.:

    Drug Monitoring of Psychiatric Patients: Methodological Aspects

  • 29
    Strauss, A.; Scherer, J.; Friedl, F.; Rüther , E.:

    The Importance of the Quantitative Description of Drug Therapy for Drug Surveillance in Psychiatry

  • 31
    Grohmann, R.; Scherer, S.; Schmidt, L. G.:

    Adverse Drug Reactions in Psychiatric Inpatients

  • 33
    Oefele, K. v; Rüther, E.:

    Adverse Drug Reaction Monitoring in Long-Term Psychiatric Inpatients

  • 35
    Haag, H.; Greil, W.; Haag, M.; Bender, W.; Rüther, E.:

    Tardive Dyskinesia and Medication History

  • 37
    Wolf, B.; Rüther, E.:

    Drug Abuse and Dependence in Psychiatric Inpatients

  • 40
    Schmidt, L. G.; Schüssler, G.; Linden, M.; Müller-Oerlinghausen, B.:

    Impact of Adverse Drug Reactions on Treatment of Psychiatric Outpatients

  • 42
    Bürke, H.:

    Drug Monitoring in Psychiatric Outpatient Treatment

  • 44
    Linden, M.; Schüssler, G.:

    Low Dosage Antidepressant Treatment in Private Psychiatric Practice - A Replication Study

  • 46
    Balss, G.; Berzewski, H.:

    The Attitude and Judgment of Psychiatrists in Private Practice in Assessing the Effect of Psychopharmaceuticals

  • 48
    Müller, J.; Hertrampf, R.; Müller-Oerlinghausen, B.:

    Exact Costs and Clinical Impact of Routine Assessments of Psychotropic Drug Serum Levels in a Psychiatric Hospital

  • 52
    Möller, H. J.; Scharl, W.; von Zerssen, D.:

    Can the Result of Neuroleptic Treatment be Predicted?
    An Empirical Investigation on Schizophrenic Inpatients

  • 54
    Schöllnhammer, G.; Spechtmeyer, H.; Hesse, C.; Husser, J.; Ebeling, H.; Parish, H. M.:

    Plasma Levels and Pharmacokinetics of Benperidol in Dog and Man

  • 56
    Schmidt, W. J.:

    How Neuroleptics Control Fixed Action Patterns

  • 58
    Schmauss, M.; Lange, E.; Nedopil, N.; Rüther, E.; Weiss-Brummer, J.:

    Effect of the Neuroleptic EMD 30-533 on Schizophrenic Symptoms: An Open Study

  • 61
    Auberger, S.; Greil, W.; Rüther, E.:

    Tiapride in the Treatment of Tardive Dyskinesia
    A Double-blind Study

  • 63
    Nedopil, N.; Eben, E.; Klein, H.; Krüger, R.; Rüther, E.; Schmauss, M.:

    High-dosage Neuroleptic Therapy for Acute Schizophrenic Patients - Two Double-blind Studies with Benperidol

  • 67
    Albus, M.; Ackenheil, M.; Müller-Spahn, F.; Naber, D.; Welter, D.:

    Do Norepinephrine Serum Levels Predict the Effects of Neuroleptic Withdrawal on Psychopathology?

  • 69
    Eben, E.; Rüther, E.:

    Animal Trial Prediction and Clinical Effect of New Chemical Substances to be Used as Antipsychotic Agents

  • 71
    Bürki, H. R.; Alder, J.; Eichenberger, E.:

    Effect of Fluperlapine on Dopaminergic Mechanisms in Rat Brain

  • 73
    Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W.:

    Fluperlapine - a Potential Successor to Clozapine

  • 75
    Arendt, G.; Heinrich, K.; Tegeler, J.; Wöller, W.; Quadbeck, H.; Klieser, E.; Lange, H.; Bremberger, R.:

    Clinical Side-Effects under Fluperlapine Therapy

  • 78
    Tegeler, J.:

    A Comparative Trial of CIS(Z)-clopenthixol-decanoate and Fluphenazine-decanoate

  • 83
    Ott, G.; Ott, C.:

    Study on the Effectiveness of Trazodone in the Treatment of Endogenous Depression. Pharmacokinetic and Psychopathometric Investigations

  • 86
    Schmauss, M.; Laakmann, G.; Dieterle, D.; Schmitz, R.; Wittmann, M.:

    Clinical Investigation on the Importance of NE-Reuptake Inhibition for Antidepressive Efficacy: Oxaprotiline versus its R-enantiomer CGP 12-103/A

  • 88
    Schmauss, M.; Laakmann, G.; Dieterle, D.:

    Nomifensine: A Double-blind Comparison of Intravenous versus Oral Administration in Therapy - Resistant Depressed Patients

  • 91
    Baumann, P.; Gaillard, J.-M.; Jonzier-Perey, M.; Gerber, C.; Bouras, C.:

    Hydroxylated Metabolites of Amitriptyline in Rat Brain After Repeated Administration of the Parent Drug

  • 94
    Kern, U.; Richter, W.:

    Clinical Comparison of Etoperidone and Amitriptyline in Endogenous Depressive Patients

  • 96
    Kissling, W.; Möller, H. J.; Lauter, H.; Binz, Ursula; Wendt, G.:

    Double-Blind Comparison of Intravenous Versus Oral Maprotiline*. Antidepressant Activity, Plasma Levels, Side-Effects

  • 98
    Woggon, B.; Angst, J.; Curtius, H. Ch.; Niederwieser, A.; Levine, R. A.; Borbély, A. A.; Tobler, I.:

    Tetrahydrobiopterin (BH4) in Endogenous Depression

  • 100
    Müller-Oerlinghausen, B.; Fähndrich, E.:

    The Relationship between Pharmacokinetic Data and the Clinical Response in Patients treated with Maprotiline or Clomipramine by Intravenous Infusion

  • 102
    Kropf, D.; Müller-Oerlinghausen, B.:

    Assessment of Visual Perception by Means of the Signal Detection Theory in Patients under Lithium Long-term Treatment*

  • 104
    Kropf, D.; Müller-Oerlinghausen, B.:

    The Influence of Lithium Long-term Medication on Personality and Mood*

  • 106
    Greil, W.; Bauer, J.; Breit, J.; Haag, M.:

    Single Daily Dose Schedule in Lithium Long-Term Treatment: Effects on Pharmacokinetics and on Renal and Cardiac Functions

  • 108
    Fähndrich, E.; Herrmann, W. M.:

    The Search for Electro-Encephalographic Variables which could Predict the Efficacy of Antidepressants

  • 110
    Trachsler, E.; Höchli, D.; Luckner, N. v; Woggon, B.:

    Dexamethasone Suppression Test before and after Partial Sleep Deprivation in Depressed Schizophrenic and Schizoaffective Patients

  • 114
    Maier, W.; Philipp, M.:

    Improving the Assessment of Severity of Depressive States: A Reduction of the Hamilton Depression Scale

  • 116
    Wacker, H. R.; Battegay, R.:

    What do Psychiatric Outpatients Think about Psychopharmacotherapy?

  • 118
    Wendt, G.; Binz, U.; Müller, A. A.:

    KUSTA (Kurz-Skala Stimmung/Aktivierung): A Daily Self-rating Scale for Depressive Patients

  • 123
    Sittig, W.; Kleindienst, G.; Irmisch, R.:

    Effects of Food Intake on CNS Activity, Psychomotor Performance and Mood States in Healthy Volunteers

  • 127
    Müller, A. A.; Binz, U.; Wendt, G.:

    Aspects of the Interpretation of Placebo-controlled Clinical Trials

  • 129
    Baumann, U.; Rösler, F.:

    The Effect of Different Instructions with Different Drugs (Placebos, Tranquilizers)

  • 131
    Classen, W.; Feingold, E.:

    Use of Placebos in Medical Practice

  • 133
    Schwalb, H.; Schimana, W.:

    Mortality in Hospitalized Psychiatric Patients
    (First Results of a 10-Year Study)

  • 134
    Höchli, D.; Trachsler, E.; Luckner, N. v; Woggon, B.:

    Partial Sleep Deprivation Therapy of Depressive Syndromes in Schizophrenic Disorders

  • 138
    Jänicke, U.-A.; Hefer, B.; Coper, H.:

    The Variable Maze: A Procedure for Testing Cognitive and Memory Performance and their Drug or Age Induced Changes

  • 141
    Menge, H. G.; Brand, U.; Kley, H.-P.:

    Classification of New CNS-active Compounds by a Two-lever Drug Discrimination Procedure

  • 143
    Kapfhammer, H.-P.; Kuss, H.-J.; Eben, E.; Rüther, E.:

    L-dopa Infusion Experiments in Combination with the L-dopa-decarboxylase Inhibitors Benserazide and Carbidopa: L-dopa Metabolism and Neuroendocrinological Effects

  • 145
    Reuß, F.; Schley, J.; Müller-Oerlinghausen, B.:

    The Relation between Serum Concentration of α1-acid Glycoprotein and Clinical Characteristics of Patients Treated with Perazine

  • 147
    Fröhler, M.; Saito, Y.; Ackenheil, M.; Bak, R.; Bondy, B.; Feistenauer, E.; Hofschuster, E.; Vakis, A.; Welter, D.:

    Catecholaminergic Binding Sites on Blood Cells of Healthy Volunteers with Special Respect to Circadian Rhythms

  • 149
    Bondy, B.; Ackenheil, M.; Bak, R.; Feistenauser, E.; Fröhler, M.:

    Catecholamine - Receptors on Blood Cells of Untreated Schizophrenic Patients

  • 151
    Syha, K.:

    Methodical Problems with α2-Receptor-binding Studies on Membrane Fragments of Blood Platelets in Clinical Investigations

  • 153
    Rommelspacher, H.; Schmidt, L.:

    Increased Formation of β-carbolines in Alcoholic Patients following Ingestion of Ethanol

  • 156
    Rickels, K.:

    Clinical Pharmacology of Benzodiazepines

  • 160
    Sieghart, W.:

    Binding of Various Benzodiazepine Receptor Ligands to Different Benzodiazepine Receptor Subtypes

  • 163
    Haefely, W.:

    Pharmacology of Benzodiazepine Antagonists

  • 167
    Stephens, D. N.; Kehr, W.; Wachtel, H.; Schmiechen, R.:

    The Anxiolytic Activity of β-Carboline Derivatives in Mice, and its Separation from Ataxic Properties

  • 171
    Emrich , H. M.; Lund, R.:

    Effect of the Benzodiazepine Antagonist Ro 15-1788 on Sleep after Sleep Withdrawal

  • 174
    Ruhland, M.; Liepmann, H.; Muesch, H. R.:

    1.2-Anellated 1.4-Benzodiazepine Derivatives - A New Class of Antipsychotics

    • BENZODIAZEPINES

  • 10
    Müller, E.:

    Benzodiazepine Receptor Interactions of Arfendazam, a Novel 1,5-Benzodiazepine*

    • DRUG SURVEILLANCE IN PSYCHIATRY

  • 26
    Helmchen, H.; Rüther, E.:

    Introduction

    • NEUROLEPTIC DRUGS

  • 50
    Möller, H. J.; Follmann, U.; Scharl, W.; von Zerssen, D.:

    Background Variables of Depressive States upon Discharge of Schizophrenic Inpatients Treated with Neuroleptics

    • ANTIDEPRESSANT DRUGS AND LITHIUM

  • 80
    Ott, C.; Ott, G.:

    Clinical Study of Trazodone in the Treatment of Patients with Endogenous Depression. Monitoring by Means of Psychopathometric Tests

    • PSYCHOLOGICAL ASSESSMENT AND NON-DRUG FACTORS IN PHARMACOTHERAPY

  • 112
    Philipp, M.; Maier, W.:

    Operational Diagnosis of Endogenous Depression. I. Comparison with Clinical Diagnosis

    • PHARMACOLOGY - BIOCHEMISTRY

  • 136
    Jänicke, B.; Wrobel, D.; Schulze, G.:

    The Effects of Various Drugs on the Motor Performance Capacity of Old Rats

    • BENZODIAZEPINES: AGONISTS AND ANTAGONISTS

  • 155
    Hippius, H.; Emrich, H. M.:

    Introduction